▎WuXiEdited by the Kant Content Team

Recently, real-world data released by the U.S. Centers for Disease Control and Prevention (CDC) showed that the vaccine jointly developed by AstraZeneca and SanofiRespiratory Syncytial Virus (RSV) prophylactic antibody Beyfortus (nirsevimab) can reduce the risk of RSV-related hospitalization in infants by 90%, surpassing previously published clinical trial data.

Data from the previous Phase 3 clinical trials showed that within 150 days after injection, Beyfortus was 81% effective (95% CI=62–90) in preventing hospitalization due to RSV-related lower respiratory tract infections. The data released by the CDC was evaluated through the New Vaccine Surveillance Network and involved an analysis of the effectiveness of Beyfortus in preventing RSV-related hospitalizations during the first RSV season between October 1, 2023, and February 29, 2024. The analysis showed,Among 699 infants hospitalized for acute respiratory illnesses, 59 (8%) received Beyfortus ≥7 days before symptom onset.Beyfortus is 90% effective (95% CI=75-96) in preventing RSV-related hospitalizations.。

The CDC noted in its published research abstract that,This early research result supports the current CDC recommendation to use Beyfortus to prevent severe RSV disease in infants.Infants should be protected through maternal RSV vaccination or by directly receiving Beyfortus.

Beyfortus is a long-acting antibody therapy designed for all infants and toddlers, requiring only one dose from birth through their first RSV season to prevent diseases associated with RSV infection.As a monoclonal antibody drug, Beyfortus provides immediate, rapid, and direct disease protection without activating the immune system. This investigational drug has received Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA) and the U.S. FDA, as well as PRIME status from the European Medicines Agency (EMA). Beyfortus was approved in November 2022.Global First ApprovalLaunched to prevent lower respiratory tract disease in newborns during their first RSV season caused by infection. Beyfortus subsequently received approval last July.FDA ApprovalListed.

Everyone is watching

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024. Retrieved March 8, 2024 from https://www.cdc.gov/mmwr/volumes/73/wr/mm7309a4.htm?s_cid=mm7309a4_w

[2] AstraZeneca, Sanofi’s Beyfortus 90% Effective at Preventing RSV Hospitalizations: CDC. Retrieved March 8, 2024 from https://www.biospace.com/article/astrazeneca-sanofi-s-beyfortus-90-percent-effective-at-preventing-rsv-hospitalizations-cdc/

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain the reprint guidelines.